Drug Type Prophylactic vaccine |
Synonyms- |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pneumococcal Infections | Phase 1 | AU | 16 Jan 2023 |
PRNewswire Manual | Phase 1 | 120 | Gamma-PN | wwoijjtumk(dyyyyzkegf) = The study met its primary safety objective, demonstrating a safety profile suitable for further development. There were no serious adverse events following administration of Gamma-PN and systemic tolerability was considered excellent. Injection site reactions were largely confined to mild to moderate erythema and swelling, typically of short (1-2 day) duration, with the frequency and extent being dose-related. Local and systemic tolerability after the second injection of Gamma-PN was similar to that after the first. iiobxogryx (gbdwdmmxwl ) View more | Positive | 03 Jan 2024 | |
Pneumovax-23 |